Polarean Imaging (POLX) AI Stock Analysis

• Market Cap: $6.94M
• Dividend Yield: N/A
• Average Volume (3M): 4.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 33.86%
• EPS Growth: 76.08%
• Country: UK
• Employees: 29
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 1,207,032,800
• 10 Day Avg. Volume: 8,262,718
• 30 Day Avg. Volume: 4,229,378
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.72
• Enterprise Value/Revenue: 4.94
• Enterprise Value/Gross Profit: 33.35
• Enterprise Value/Ebitda: -2.01
• 1Y Price Target: $3.75
• Price Target Upside: 649.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: 1.00p ▲(100.00% Upside)

Polarean Imaging's overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. Although recent corporate events are positive, they are not enough to offset the significant financial and technical challenges.

Positive Factors

Negative Factors

Polarean Imaging Business Overview & Revenue Model

Company Description

Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.

How the Company Makes Money

Polarean Imaging generates revenue primarily through the sale of its Polarean System and related services, including installation, maintenance, and training for medical facilities. Additionally, the company may earn revenue from selling hyperpolarized gas products used in conjunction with its imaging technology. Key revenue streams include direct sales to hospitals and research institutions, strategic partnerships with healthcare providers, and potential collaborations with pharmaceutical companies for clinical trials and research purposes. The company's financial success is bolstered by the growing demand for advanced imaging solutions and the increasing prevalence of respiratory diseases that require innovative diagnostic methods.

Polarean Imaging Financial Statement Overview

Summary

Polarean Imaging exhibits a challenging financial position with volatile revenue growth and persistent losses impacting profitability. Despite a strong equity base and low leverage, the continuous cash flow deficits pose a risk. The company needs to improve operational efficiency to achieve sustainable financial health.

Income Statement

Polarean Imaging has shown inconsistency in revenue growth, with significant fluctuations over the years. The gross profit margin is moderate, but the company struggles with negative EBIT and net profit margins. The most recent year shows a substantial increase in revenue, yet profitability remains a challenge.

Balance Sheet

The balance sheet reflects a strong equity position, but the company carries some debt. The debt-to-equity ratio is low, indicating low leverage, but continuous losses have impacted the equity base. Despite this, the equity ratio remains healthy, showcasing good capital management.

Cash Flow

Cash flow statements show persistent negative free cash flow, indicating ongoing operational losses. While financing activities have provided liquidity, the operating cash flow to net income ratio highlights inefficiencies in converting income to cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.09M	890.93K	1.03M	1.19M	1.06M
Gross Profit	1.42M	335.48K	348.28K	508.02K	710.47K
EBITDA	-7.56M	-10.93M	-12.84M	-13.38M	-5.73M
Net Income	-8.54M	-11.88M	-14.14M	-13.72M	-6.55M
Balance Sheet
Total Assets	15.79M	10.88M	22.54M	34.53M	10.88M
Cash, Cash Equivalents and Short-Term Investments	12.11M	6.17M	16.45M	28.87M	6.28M
Total Debt	503.79K	216.69K	358.84K	489.79K	221.43K
Total Liabilities	3.65M	2.58M	3.23M	2.79M	2.15M
Stockholders Equity	12.14M	8.30M	19.30M	31.74M	8.73M
Cash Flow
Free Cash Flow	-5.81M	-10.51M	-12.32M	-12.79M	-5.86M
Operating Cash Flow	-5.61M	-10.43M	-12.26M	-12.25M	-5.79M
Investing Cash Flow	77.20K	219.98K	-63.95K	-541.45K	-65.53K
Financing Cash Flow	11.52M	-140.04K	147.62K	35.38M	10.18M

Polarean Imaging Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:POLX, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.91, and below the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 21.79 is Positive, neither overbought nor oversold. The STOCH value of 24.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:POLX.

Polarean Imaging Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRX	49 Neutral	16.74M	-28.21	-2.39%	―	-5.33%	60.20%
SAR	47 Neutral	37.27M	-14.97	―	―	―	71.17%
CREO	44 Neutral	50.53M	-2.01	-67.69%	―	―	―
POLX	41 Neutral	$6.94M	―	-80.95%	―	33.86%	76.08%
IHC	40 Underperform	19.28M	-1.20	-89.97%	―	1.65%	-102.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Polarean Imaging Corporate Events

Polarean Imaging Seeks FDA Approval for Expanded Use of XENOVIEW®

Polarean Imaging plc has submitted a new Phase III clinical trial protocol to the FDA to expand the indication of its XENOVIEW® contrast agent to include quantitative gas-exchange imaging. This expansion aims to enhance the clinical utility of XENOVIEW by enabling comprehensive lung function assessment, which could significantly impact the diagnosis and treatment of various pulmonary diseases. The FDA’s review of this protocol is expected to conclude by Q4 2025, marking a critical milestone in Polarean’s growth strategy and its mission to transform pulmonary imaging.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Polarean Imaging Partners with Ascend Imaging to Boost US Market Growth

Polarean Imaging has entered into a Representative Agreement with Ascend Imaging to promote and sell its Xenon MRI platform in four US states. This partnership aims to enhance Polarean’s market reach and commercial momentum by leveraging Ascend Imaging’s expertise in radiology and strong customer relationships, supporting Polarean’s strategic expansion in the US market.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Polarean Imaging Expands XENOVIEW® Indication to Younger Patients

Polarean Imaging Plc announced that the FDA has approved the expansion of its XENOVIEW® indication to include children aged six and older, increasing the number of eligible patients by approximately one million. This approval allows for broader access to the company’s technology, enhancing its clinical utility and market reach. The introduction of new Dose Delivery Bag sizes for younger patients and updates to the HPX Polarisation Measurement Station further support the company’s commitment to advancing lung imaging and providing personalized care for children with chronic respiratory conditions.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Polarean’s Dr. Bastiaan Driehuys Honored for Xenon MRI Innovations

Polarean Imaging announced that Dr. Bastiaan Driehuys, its Chief Scientific Officer, received the 2025 American Thoracic Society Respiratory Health Award for his pioneering work in Xenon MRI technology. This recognition highlights the impact of Dr. Driehuys’ contributions to pulmonary imaging, which have advanced the science and improved patient outcomes by enabling earlier detection and better treatment planning for respiratory conditions.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Polarean Imaging’s Xenon MRI to Take Center Stage at ATS 2025

Polarean Imaging plc’s Xenon MRI technology will be prominently featured at the American Thoracic Society’s 2025 Respiratory Innovation Summit and International Conference, highlighting its growing recognition as a pivotal tool in respiratory care. With over 30 presentations from leading clinical sites, the technology’s versatility across various respiratory conditions is showcased, reinforcing its role in both clinical care and trials. This presence underscores Polarean’s position at the forefront of respiratory medicine, as the company continues to engage with industry leaders and stakeholders to advance functional lung imaging.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Polarean and Philips Collaborate to Advance Pediatric Lung MRI Technology

Polarean Imaging has announced a continued collaboration with Philips to expand the use of advanced Xenon lung MRI technology for children with chronic obstructive lung disease. This partnership is expected to enhance Polarean’s market position by broadening the application of its innovative imaging solutions, potentially benefiting stakeholders by addressing significant healthcare needs in pediatric respiratory medicine.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.